Navigation Links
Novavax Reports First Quarter 2009 Financial Results

could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

                               NOVAVAX, INC.
          (in thousands, except per share and per share information)

                                                           Three-month ended
                                                         March 31,  March 31,
                                                           2009       2008
         Total revenues                                     $21         458

     Operating costs and expenses:
       Research and development                           4,266       4,434
       General and administrative                         2,892       3,244

         Total operating costs and expenses               7,158       7,678

     Loss from continuing operations before interest     (7,137)     (7,220)
     Interest income, (loss), net                        (1,212)        117

     Loss from continuing operations                     (8,349)     (7,103)
     Loss from discontinued operations                        -        (652)

     Net loss                                            (8,349)     (7,755)

     Basic and diluted weighted average
       number of common shares used in
       computing basic net loss per share            68,692,455  61,280,155

     Basic and diluted net loss per share
       Loss per share from continuing operations         $(0.12)     $(0.12)
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
(Date:10/8/2015)... WILMINGTON, Del. , Oct. 8, 2015 /PRNewswire/ ... of CRISPR-Cas technologies for genome editing, jointly announced ... DuPont and Caribou have cross-licensed their respective patent portfolios, ... CRISPR-Cas technology applications in major row crops, and ... applications. --> ...
(Date:10/8/2015)... LOUIS , Oct. 8, 2015  Sigma-Aldrich ... the Cerilliant ® brand within its Applied ... new bile acid reference standards product line with ... most routinely tested bile acids and their stable-labeled ... (CRMs) consist of lithocholic acid, taurocholic acid and ...
(Date:10/7/2015)... India , October 8, 2015 /PRNewswire/ ... --> Medical biotechnology accounts for largest ... of bioinformatics in drug discovery and development ... . ... On the basis of applications, the ...
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. (OTCQX: ... nutritional ingredients that creates science-based solutions for dietary ... and pharmaceutical products, today announced that the October ... and Founder, is now available for on-demand viewing ... -->   --> ...
Breaking Biology Technology:
... ATLANTA, Oct. 20 GeoVax Labs, Inc. ... "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for ... infectious agents, today announced that it will move its ... of Emory University to Smyrna, Georgia, a northwest suburb ...
... scar Custance from the National Institute for Materials Science in ... Experimental Work in Nanotechnology for his research in atomic-scale precision. ... to more effective catalysts for the production of hydrogen fuel. ... awarded in January 2010 near Palo Alto, California along with ...
... - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: ... endocrine therapy and oncology, announced today that it has ... of common shares and common share purchase warrants in ... Securities Purchase Agreement, the Company will sell to such ...
Cached Biology Technology:
(Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
(Date:9/8/2015)... Sept. 8, 2015   TREW Marketing and ... survey, Smart Marketing for Engineers TM : Content ... professionals reveals insightful findings about engineers, preferences for online ... content engineers most value and trust, and where they ... targeting technical audiences grapple with how to best implement ...
(Date:9/1/2015)... Sept. 1, 2015  Automation and pre-processing are ... passenger screening. This is the first step toward ... will become unintrusive. An assortment of portal scanners, ... background investigations will transform the passenger screening process. ... Global Airport Passenger Screening Market ( ...
Breaking Biology News(10 mins):
... an outbreak of the bee infection American foulbrood in Jersey, ... diseases such as European foulbrood and the Varroa ... the method also allows scientists to simulate various disease control ... used two sets of data gathered two months apart during ...
... , ,A new EU project, METSY, develops and ... lipid metabolism is connected to psychotic disorders and ... , The overall objective is to identify, prioritize ... have diagnostic potential for prediction and monitoring psychotic ...
... (16 SEPTEMBER 2013)Kenyan farmers and agriculture officials need ... maize production as climate change threatens to make ... for cultivation while simultaneously making others more maize-friendly, ... International Food Policy Research Institute (IFPRI) and the ...
Cached Biology News:
... Mutation Explorer processes up to 48 ... traces. Data input can be from either ... terminator or primer chemistries. The detection parameters ... analyst to analyst consistency. We have ...
... graphic manipulation of DNA sequences and sophisticated ... winning interface design that allows graphic manipulation ... sophisticated drawing capabilities for Mac and Windows ... Mapping Software" by the Biotechnology Software and ...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: